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Abstract
Background: The current study examines unstaged disease for 18 cancer sites in the United States according to
the influence of age, sex, race, marital status, incidence, and lethality.
Methods: Analyses are based on 1,040,381 male and 1,011,355 female incident cancer cases diagnosed during
2000 through 2007. Data were collected by population-based cancer registries in the National Cancer Institute’s
Surveillance, Epidemiology, and End Results Program.
Results: The level of unstaged disease was greater in more lethal cancers (e.g., liver, esophagus, and pancreas)
compared with less deadly cancers (i.e., colon, urinary bladder, and female breast). Unstaged disease increased with
age and is greater among non-married patients. Blacks compared with whites experienced significantly higher
levels of unstaged cancers of the stomach, rectum, colon, skin (melanoma), urinary bladder, thyroid, breast, corpus,
cervix, and ovaries, but lower levels of unstaged liver, lung and bronchial cancers. Males compared with females
experienced significantly lower levels of unstaged cancers of the liver, pancreas, esophagus, and stomach, but
significantly higher levels of unstaged lung and bronchial cancer and thyroid cancer. The percent of unstaged
cancer significantly decreased over the study period for 15 of the 18 cancer sites.
Conclusion: Tumor staging directly affects treatment options and survival, so it is recommended that further
research focus on why a decrease in unstaged disease did not occur for all of the cancer sites considered from
2000 to 2007, and why there are differential levels of staging between whites and blacks, males and females for
several of the cancer sites.
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Background
Cancer staging, an important prognostic indicator, pro-
vides direction on an appropriate course of treatment.
However, each year a small percentage of newly diag-
nosed cancers are not assigned a tumor stage. In a study
involving postmenopausal women with breast cancer in
the United States (U.S.), increased age was significantly
associated with decreased staging of the tumor and with
fewer auxiliary lymph node dissections in women aged
70 years and older [1]. The association between older
age and decreased staging of the tumor was also identi-
fied in studies involving prostate cancer, as well as colon
and rectal cancers in the U.S. [2-5]. In addition to the
association between advancing age and unknown tumor
stage, studies revealed that more vulnerable patients,
such as minority groups, patients requiring more com-
plex care needs in long-term care settings, those with
lower education levels, and the uninsured are more
likely to have unstaged cancer [2-6].
Components of staging include tumor size (T), num-
ber of lymph nodes (N), and metastases (M). When
examining the contribution that missing TNM informa-
tion has on unstaged colon and rectal cancers,
Worthington and colleagues observed that M was miss-
ing for most colon and rectal cancer cases with unstaged
disease [4]. Refusal to undergo diagnostic testing and
treatment or an inoperable tumor possibly contributed
to missing information. The authors also suggested that
unknown stage may have resulted if patients were only
treated with endoscopic therapy and local excision, or
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available.
Thus far, the study of unstaged disease has focused
primarily on cancers of the breast, prostate, colon and
rectum. The purpose of this study is to identify the level
of unknown-staged disease for 18 major cancer sites in
the U.S., identify changes in the level of unknown sta-
ging for the selected cancer sites from 2000 through
2007, identify the influence of age, sex, race, and marital
status on the level of unstaged disease for the selected
cancer sites, and identify how the incidence rate and
lethality of the cancer is associated with the level of
patient staging for that disease.
Methods
Data
Analyses are based on 2,726,147 newly diagnosed cancer
cases during 2000 through 2007 collected from medical
records at hospitals and other facilities by 17 popula-
tion-based cancer registries in the Surveillance, Epide-
miology, and End Results (SEER) Program of the
National Cancer Institute [7]. The SEER Program was
established in response to the National Cancer Act of
1971, which mandated public health surveillance of can-
cer in the U.S. for use in prevention, diagnosis, and
treatment of cancer. The SEER Program began collect-
ing data on cancer cases on January 1, 1973, with seven
registries (Connecticut, Iowa, New Mexico, Utah, and
Hawaii, and the metropolitan areas of Detroit and San
Francisco-Oakland). In the following two years the
metropolitan area of Atlanta and the 13-county Seattle-
Puget Sound area were added. In 1992, the SEER Pro-
gram was expanded to increase coverage of minority
populations to include 10 primarily black rural counties
in Georgia, the Alaska Native population, Los Angeles
County, and four counties in the San Jose-Monterey
area south of San Francisco. In 2000, the SEER Program
further expanded coverage to include Kentucky and the
remaining counties in California (Greater California); in
addition, New Jersey and Louisiana once again became
participants (Surveillance, Epidemiology, and End
Results [SEER] Program [http://www.seer.cancer.gov])
[8]. These areas cover 26% of the U.S. population (23%
of African Americans, 40% of Hispanics, 42% of Ameri-
can Indians and Alaska Natives, and 59% of the Asian/
Pacific Islander population) [8].
Among the newly diagnosed cancer cases, 2,493,516
(91%) were classified as non-Spanish-Hispanic-Latino
(83% white, 10% black, 1% American Indian/Alaska
Native, and 6% Asian or Pacific Islander) and 232,631
(9%) were classified as Spanish-Hispanic-Latino (97%
white, 1% black, 1% American Indian/Alaska Native, and
1% Asian or Pacific Islander).
The tumor registries participating in the SEER Pro-
gram routinely abstract records of all cancer patients in
hospitals, clinics, nursing homes, and other health ser-
vice units that provide diagnostic or treatment services;
from private pathology laboratories and radiotherapy
units; and from death certificates. Data collected by the
tumor registries include patient demographics, tumor
characteristics, morphology, diagnostic information,
extent of disease, first course of treatment, and active
patient follow-up of vital status including cause of
death. Cancers are coded according to the International
Classification of Disease for Oncology Second Edition
(ICD-O-2) [9]. This study uses the SEER historic sum-
mary stage classification to identify unstaged disease.
Cancer frequencies, rates, and survival probabilities
were calculated using the SEER Survival System (SEER*-
Stat) (Surveillance Research Program, National Cancer
Institute SEER*Stat software [http://www.seer.cancer.
gov/seerstat] version 6.6.2).
Variables
Eighteen cancer sites were selected for study: liver, pan-
creas, esophagus, stomach, lung and bronchus, soft tis-
sues, prostate, kidney and renal pelvis, oral cavity and
pharynx, colon, rectum, melanoma of the skin, urinary
bladder, thyroid, cervix uteri, breast (female), corpus
uteri, and ovary. These sites were selected because they
provide a representation of more and less common can-
cers, more and less lethal cancers, and cancers specific
to the male and female genital systems. In addition, age
(0-59, 60-79, and 80 years or older), sex, race (whites,
blacks), and marital status (married [or cohabitating] or
single), ethnicity, and Appalachia residence status were
included as variables in the study.
Statistical Techniques
Cancer site-specific percentages of unstaged disease
were calculated by dividing the age-adjusted malignant
incidence rate of unstaged disease by the total age-
adjusted incidence rate. Rates were age-adjusted using
the 2000 U.S. standard population. In a multiple regres-
sion model, the percentage of unstaged cancer was
regressed on calendar year (2000 through 2007), race
(white, black), and sex, and evaluated for statistical sig-
nificance using the F test. The percentage of unstaged
cancer was also regressed on age, sex, race, and marital
status separately for each of the selected cancer sites.
Interaction terms were assessed in the model between
age, sex, race, and marital status with cancer site. Multi-
ple regression models were used to evaluate whether the
level of unstaged cancer was associated with malignant
incidence rates for the selected cancers and also if the
level of unstaged cancer was associated with the cancer
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sex, and race.
We used relative survival to circumvent the problem
associated with tumor registries of inaccurate or unavail-
able death certificates and the uncertainty about the
cause of death [10-12]. Relative survival is the ratio of
the proportion of observed survivors in a cohort of can-
cer patients to the proportion of expected survivors in a
comparable set of cancer free individuals. The formula-
tion is based on the assumption of independent compet-
ing causes of death. The relative survival adjusts for the
general survival of the U.S. population for the race, sex,
age, and date at which the age was coded. If age, race,
sex, or year information is missing, that individual is
excluded from the analysis. Standard case selection cri-
teria employed by the SEER Program were used; that is,
cases were selected if they were actively followed and
had malignant behavior and a known age. Cases were
excluded if they were a second or later primary. Death
certificate-only and autopsy-only cases were also
excluded. Patients diagnosed between 2000 and 2007
were included, with follow-up through 2007.
Analyses were performed using the Statistical Analysis
System (SAS) software, version 9.2 (SAS Institute Inc.,
Cary, NC, USA, 2007).
Results
The level of unstaged disease is presented for 18
selected cancer sites for white and black patients in Fig-
ure 1. The highest levels of unstaged disease occur in
cancers of the liver, esophagus, and pancreas and the
lowest levels involve cancers of the colon, urinary blad-
der, and female breast. Unstaged disease for white and
black patients increases sharply with age, with the great-
est percent increase observed in cancers of the pancreas,
lung and bronchus, kidney and renal pelvis, prostate,
and ovaries. For several of the cancer sites, there is also
a significant positive association between staging and
being married (Figure 2). In addition, for all racial
groups, patients of Spanish-Hispanic-Latino descent
(Figure 3) and residents of Appalachia (Figure 4) were
significantly more likely to have their cancer unstaged.
Trends in unstaged disease for white and black
patients are presented for each of the selected cancer
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Figure 1 Percentages of Unstaged Disease for Selected Cancer Sites According to Age. Adjusted for sex. Source: Surveillance,
Epidemiology, and End Results (SEER) 2000-2007.
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ease occurred for each of the cancers, with the excep-
tion of malignancies of the oral cavity and pharynx,
melanoma of the skin, cervix, and the thyroid, where no
significant change occurred, and stomach cancer, where
an increase in unstaged disease occurred. Blacks had sig-
nificantly higher levels of unstaged cancers of the sto-
mach, rectum, colon, skin (melanoma), urinary bladder,
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Figure 2 Percentages of Unstaged Disease for Selected Cancer Sites According to Marital Status. Adjusted for age and sex. Source:
Surveillance, Epidemiology, and End Results (SEER) 2000-2007.
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and ovaries. On the other hand, blacks with liver cancer
or lung and bronchial cancer were significantly more
likely to have their tumor staged. Males compared with
females experienced significantly lower levels of
unstaged cancers of the liver, pancreas, esophagus, and
stomach, but significantly higher levels of unstaged lung
and bronchial cancer and thyroid cancer. There was a
significant statistical interaction involving sex and race
in the model for thyroid cancer. Among males, blacks
had a significantly higher level of unstaged thyroid can-
cer (2.04%, P = 0.007), but among females, there was no
significant difference in the level of unstaged thyroid
cancer.
There was no significant association between the level
of unstaged disease and incidence rates for the selected
cancer sites, with the exception of white females (Table
2). For this group, cancer sites with higher incidence
rates had significantly lower unstaged disease. We also
assessed the association between the level of unstaged
disease and five-year relative survival for the selected
cancer sites. For males and females, whites and blacks,
cancer sites with greater five-year survival had lower
unstaged disease.
Discussion
Percentages of unstaged disease increased significantly
with age for each of the 18 selected cancer sites, as con-
sistent with previous studies [1-5,13]. Age and comorbid
conditions limit one’s ability to undergo testing and
examinations. Neither elderly patients nor their family
members may consent to a diagnostic workup [3]. This
is especially the case when older patients have compet-
ing health problems that limit disease investigation. In a
study involving elderly postmenopausal breast cancer
patients, the authors concluded that compromised
health status associated with age may have precluded
patients from obtaining certain prognostic information
(e.g., Axillary lymph node dissection [AxLND] for breast
cancer patients), which in turn can limit treatment
options [1].
Married individuals were significantly more likely to
receive a cancer staging, after adjusting for age, sex, and
race. Previous studies have not specifically considered
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Figure 3 Percentages of Unstaged Disease According to Ethnicity and Sex. Adjusted for age. Source: Surveillance, Epidemiology, and End
Results (SEER) 2000-2007.
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ever, this result is consistent with findings from studies
showing that married cancer patients tend to be identi-
fied at an earlier stage of disease, experience fewer
comorbid conditions, and have better prognosis [14-16].
One study reported that married individuals have higher
socioeconomic status and social support, which in turn
leads to higher survival than non-married individuals
[17]. Older women who are assigned an advanced
tumor stage or no tumor stage at diagnosis are more
likely to be widowed than younger women, who will
also have a higher chance of survival. Another study
found that women who were married, white or of higher
socioeconomic status were more likely to undergo mam-
mography and receive pap testing than single women
[16]. Married women enjoy the benefit of a combined
income and a stable partner, which increases their likeli-
hood of being able to afford appropriate medical
services.
The higher percentage of unstaged cases who are of
Spanish-Hispanic-Latino descent or who reside in Appa-
lachia may be explained, at least in part, by lower levels
of health insurance, which limits one’s ability to undergo
testing and examinations. Culture may also influence the
patient’s willingness to consent to a diagnostic workup.
In addition, a thorough cancer workup is more limited
among patients of poorer overall health status. Further
research focusing on cancer staging by ethnicity and
Appalachia status is warranted.
The percentage of cases receiving an unknown stage
assignment decreased over the study period for 15 of
the 18 cancer sites considered. Other studies focusing
on colon and rectal cancers and prostate cancer also
observed a decrease in unknown staging [2,4]. Reasons
for this increase in staging may include physician educa-
tion, introduction of less invasive staging procedures,
and adoption of a collaborative staging system by SEER
in 2004, which combines and standardizes information
using computer algorithms to assign a stage.
This study also revealed a higher percentage of
unstaged rectal cancer than colon cancer. The authors
of another study likewise observed a higher percentage
of unstaged rectal cancer than colon cancer, attributing
this to the limited availability of endoscopic ultrasounds
often required for staging rectal cancer [2]. However,
the same screening methods are typically used to detect
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Figure 4 Percentages of Unstaged Disease According to Appalachia Residence and Sex. Adjusted for age. Source: Surveillance,
Epidemiology, and End Results (SEER) 2000-2007.
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ods (e.g., sigmoidoscopy) are more likely to detect can-
cers of the rectum or distal colon.
Two previous SEER data-based studies identified that
the percentage of unstaged colorectal cancer was signifi-
cantly lower for males than females [3,4]. In the current
study, we found no significant difference in the percen-
tage of unstaged colon or rectal cancers between males
and females, after adjusting for age and race. However,
in rerunning the models without adjusting for these
variables, a similar result was found to those in the pre-
vious studies. The large difference in life expectancy
between males and females in the U.S. emphasizes the
need to adjust for the potential confounding effect of
age. In addition, some researchers have identified that
older males in the U.S. tend to have higher socioeco-
nomic status than their female counterparts, and that
older women are more likely to be insured by Medicaid
[3]. Patients with advanced age and covered by Medicaid
have a higher probability of having their cancer recorded
as unknown.
Lower screening rates among females for esophageal
and stomach cancers may explain significantly higher
rates of unstaged disease for females compared to males
after adjusting for age and race. For example, one study
involving stomach cancer reported that 32.5% of men
compared with 23.5% of women underwent screening
Table 1 Estimated effects of calendar year, race, and sex
on percent of selected site-specific unstage cancer
Estimate* P Value
†
Liver
Year -1.28% < 0.001
Race (Black vs. White) -2.67% < 0.001
Sex (Male vs. Female) -1.77% 0.012
Pancreas
Year -0.77% < 0.001
Race (Black vs. White) -0.24% 0.675
Sex (Male vs. Female) -1.65% 0.006
Esophagus
Year -0.66% 0.003
Race (Black vs. White) 1.92% 0.051
Sex (Male vs. Female) -4.84% < 0.001
Stomach
Year 0.32% 0.008
Race (Black vs. White) 2.07% < 0.001
Sex (Male vs. Female) -2.11% < 0.001
Lung and bronchus
Year -0.32% < 0.001
Race (Black vs. White) -0.72% 0.006
Sex (Male vs. Female) 0.51% 0.047
Soft tissues
Year -0.36% 0.026
Race (Black vs. White) -0.51% 0.470
Sex (Male vs. Female) 0.41% 0.561
Rectum
Year -0.29% 0.019
Race (Black vs. White) 4.48% < 0.001
Sex (Male vs. Female) -0.32% 0.552
Oral cavity and pharynx
Year 0.12% 0.462
Race (Black vs. White) -0.06% 0.930
Sex (Male vs. Female) -0.20% 0.780
Colon
Year -0.18% < 0.001
Race (Black vs. White) 1.58% < 0.001
Sex (Male vs. Female) 0.08% 0.734
Kidney and renal pelvis
Year -0.36% < 0.001
Race (Black vs. White) 1.19% < 0.001
Sex (Male vs. Female) 0.19% 0.524
Prostate
Year -0.49% < 0.001
Race (Black vs. White) 0.52% 0.108
Melanoma of the skin
Year 0.14% 0.666
Race (Black vs. White) 4.63% 0.004
Sex (Male vs. Female) -1.89% 0.206
Urinary bladder
Year -0.19% 0.030
Table 1 Estimated effects of calendar year, race, and sex
on percent of selected site-specific unstage cancer
(Continued)
Race (Black vs. White) 2.29% < 0.001
Sex (Male vs. Female) -0.49% 0.200
Thyroid
Year -0.13% 0.155
Race (Black vs. White) 1.13% 0.010
Sex (Male vs. Female) 1.02% 0.019
Female Breast
Year -0.18% < 0.001
Race (Black vs. White) 0.89% < 0.001
Corpus Uteri
Year -0.26% 0.002
Race (Black vs. White) 2.62% < 0.001
Cervix
Year -0.16% 0.295
Race (Black vs. White) 2.64% 0.002
Ovary
Year -0.39% 0.019
Race (Black vs. White) 3.69% < 0.001
Data source: Surveillance, Epidemiology and End Results (SEER) Program,
2000-2007.
*Estimates in each model are adjusted for calendar year, race, and sex.
†Based on the F value.
Merrill et al. BMC Cancer 2011, 11:402
http://www.biomedcentral.com/1471-2407/11/402
Page 7 of 10for the disease [18]. Of those who were screened,
approximately half were screened at work, which sug-
gests that unemployed women are less likely to be
screened. (Note that in the U.S., only high risk indivi-
duals are recommended to pursue esophageal or sto-
mach cancer screening [19].) Also, because stomach
cancer is more prevalent among males than females,
females are less motivated to undergo screening for this
disease–especially since no routine stomach cancer
screening method exists [19].
Black males were less likely than white males to be
assigned a tumor stage for cancers involving the sto-
mach, rectum, colon, kidney and renal pelvis, and thyr-
oid. Black females were less likely than white females to
be assigned a tumor stage for cancers involving the
breast, corpus, cervix, and ovaries. Higher levels of
unstaged disease among blacks have been observed in
other studies [4,6,20]. A higher level of unstaged disease
among blacks compared with whites is consistent with
their tendency to be diagnosed at a later stage, to have
more comorbid conditions, and to experience poorer
survival rates [20,21]. Poorer survival among unstaged
patients may be explained by lower levels of treatment
[1,4-6,12,22] In addition, unstaged patients who do not
receive surgery tend to experience more severe comor-
bidities than patients that receive treatment [1].
Although unstaged disease influences treatment out-
comes, age and comorbid conditions are contributing
factors since they are negatively associated with cancer-
directed therapy [5].
One study found that uninsured patients are less likely
to receive a tumor stage than insured patients [6].
Another study observed that poorer socioeconomic sta-
tus among blacks is associated with generally more
Table 2 Site-specific percentage of unstage cancer, malignant cancer incidence rates, and 5-year relative survival
according to race and sex
White Males White Females Black Males Black Females
Unstage
%*
Malignant
Incidence
Rate
†
5-yr
Survival
%
‡
Unstage
%*
Malignant
Incidence
Rate
†
5-yr
Survival
%
‡
Unstage
%*
Malignant
Incidence
Rate
†
5-yr
Survival
%
‡
Unstage
%*
Malignant
Incidence
Rate
†
5-yr
Survival
%
‡
Liver 20.3 7.9 10.9 24.0 2.5 12.9 17.8 12.8 6.4 18.9 3.6 9.9
Pancreas 14.4 13.1 4.4 15.7 10.2 4.6 13.9 16.5 3.9 16.1 14.3 5.2
Esophagus 13.9 8 14.1 21.1 1.9 14.2 16.7 9.6 7.2 22.6 3.0 10.3
Stomach 12.1 9.9 18.6 14.9 4.7 23.5 14.5 17.2 19.5 15.6 9.0 25.4
Lung and
bronchus
8.6 78.9 12.9 8.4 54.9 17.7 8.2 106.1 10.7 7.4 54.3 14.4
Soft tissues 7.7 3.9 66.5 7.4 2.7 66.5 8.6 3.6 60.2 6.7 3.1 63.4
Rectum 7.1 12.7 60.4 7.9 7.6 61.6 11.3 12.4 51.9 11.8 8.5 57.5
Oral cavity and
pharynx
6.3 15.8 58.2 6.6 6.1 61.3 6.5 16.9 33.1 6.9 5.7 49.9
Colon 5.2 40.5 61.6 5.3 32 61.3 7.0 52.7 53.3 6.8 42.3 53.8
Kidney and
renal pelvis
5.2 19.1 63.9 5.2 9.7 64.1 7.0 21.3 60.8 6.7 10.4 64.2
Prostate 4.9 158 93.4 5.4 248.2 88.9
Melanoma of
the skin
3.8 28.9 86.8 3.8 18.6 92.2 8.3 1.1 65.1 11.1 0.9 76.1
Urinary
bladder
3.2 40.6 80.9 4.0 9.9 75.8 5.4 20.5 67.7 5.2 7.6 53.4
Thyroid 2.0 5.1 93.5 2.1 14.7 97.4 3.7 2.7 88.8 2.4 8.2 94.9
Female Breast 2.1 130.7 86.1 3.0 119.1 73.5
Corpus Uteri 3.3 24 86 5.7 19.2 60.8
Cervix 4.8 8.3 71.3 7.4 10.7 61.1
Ovary 7.1 14.1 42.9 10.8 10.1 38.8
Spearman’s
Rho
-0.38 -0.92 -0.62 -0.93 -0.31 -0.80 -0.32 -0.70
P Value 0.179 < 0.001 0.008 < 0.001 0.283 < 0.001 0.216 0.002
Data source: Surveillance, Epidemiology and End Results (SEER) Program, 2000-2007.
*Age-adjusted to the 2000 US standard population.
†Age-adjusted to the 2000 US standard population and expressed per 100,000.
‡Relative survival, which is a net survival measure representing cancer survival in the absence of other causes of death.
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vix [23], which in turn could explain higher levels of
unstaged disease [5]. Lower socioeconomic status is
likely associated with blacks seeking medical care later
in the disease process, which in turn influences their
higher levels of unstaged disease. With a greater propor-
tion of unstaged disease among minorities, race-stage
information may be biased.
Only for white females were the cancer sites with
higher incidence rates significantly associated with lower
unstaged disease. This may be because of increased cost
associated with rare cancer diagnosis and treatment
[24]. Individuals with rare cancers will probably need
more sophisticated diagnostic procedures in general,
and those who refuse such procedures because of age or
monetary factors will be more likely to receive an
unknown tumor stage diagnosis.
We observed a strong and consistent association
between cancer sites with better survival having lower
unstaged disease. For patients with poor prognosis, can-
cer staging may not be necessary. On the other hand,
not receiving a tumor stage may result in not receiving
life extending treatment.
Strengths and weaknesses of the SEER data need some
consideration. Cancer registries in the SEER Program
incorporate several quality assurance measures, identify
nearly all diagnosed cases in their catchment areas, and
have a very high level of follow-up for vital status. Cri-
teria used by SEER regarding formatting and defining
case information are described elsewhere [25,26]. SEER
data provide a large number of cases with detailed infor-
mation on patient demographics, tumor characteristics,
morphology, diagnostic information, and extent of dis-
ease. This allowed us to adjust for selected factors while
assessing unstaged disease. In addition, the 17 SEER
registries included in this study cover approximately
26% of the U.S., with both urban and rural areas repre-
sented. Hence, the results have a high level of external
validity. One study found that the SEER coverage area
may under represent tobacco-related cancers [27].
While SEER does not collect data on comorbid diseases
for conditions other than cancer, relative survival pro-
vided us with a measure of net survival (survival in the
absence of other causes).
Conclusion
Poor health status, higher levels of comorbid diseases,
greater difficulty in obtaining health insurance and more
inoperable tumors associated with advancing age may
have precluded some patients from obtaining tumor sta-
ging, which in turn limited treatment options and survi-
val. These conditions may also have been more common
in unmarried patients, thereby explaining their higher
levels of unstaged disease. For 10 of the 18 cancer sites
considered, blacks experienced higher levels of unstaged
disease. Males had a lower level of unstaged disease for
four of the cancer sites but a higher level of unstaged dis-
ease for two of the cancer sites. A significant decrease in
unstaged disease occurred for 15 of the 18 cancer sites
considered. Understanding reasons for a decrease in
unstaged disease did not occur for all of the cancer sites
considered. Further studies should explore reasons for
differential levels of staging between whites and blacks,
males and females for several of the cancer sites.
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